CARDURA Drug Patent Profile

✉ Email this page to a colleague

Which patents cover Cardura, and when can generic versions of Cardura launch?

Cardura is a drug marketed by Viatris and is included in two NDAs.

The generic ingredient in CARDURA is doxazosin mesylate. There are fourteen drug master file entries for this compound. Thirty-one suppliers are listed for this compound. Additional details are available on the doxazosin mesylate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Cardura

A generic version of CARDURA was approved as doxazosin mesylate by APOTEX on October 18^th, 2000.

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for CARDURA?
What are the global sales for CARDURA?
What is Average Wholesale Price for CARDURA?

Summary for CARDURA

US Patents:	0
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	106
Clinical Trials:	11
Patent Applications:	1,730
Drug Prices:	Drug price information for CARDURA
What excipients (inactive ingredients) are in CARDURA?	CARDURA excipients list
DailyMed Link:	CARDURA at DailyMed

Drug patent expirations by year for CARDURA

Recent Clinical Trials for CARDURA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
The University of Texas Health Science Center, Houston	Phase 1
Brown University	Phase 2
University of California, Los Angeles	Phase 3

See all CARDURA clinical trials

Pharmacology for CARDURA

Drug Class	alpha-Adrenergic Blocker
Mechanism of Action	Adrenergic alpha-Antagonists

US Patents and Regulatory Information for CARDURA

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Viatris	CARDURA	doxazosin mesylate	TABLET;ORAL	019668-001	Nov 2, 1990	AB	RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Viatris	CARDURA	doxazosin mesylate	TABLET;ORAL	019668-004	Nov 2, 1990	AB	RX	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Viatris	CARDURA	doxazosin mesylate	TABLET;ORAL	019668-002	Nov 2, 1990	AB	RX	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for CARDURA

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Viatris	CARDURA	doxazosin mesylate	TABLET;ORAL	019668-004	Nov 2, 1990	⤷ Sign Up	⤷ Sign Up
Viatris	CARDURA	doxazosin mesylate	TABLET;ORAL	019668-001	Nov 2, 1990	⤷ Sign Up	⤷ Sign Up
Viatris	CARDURA	doxazosin mesylate	TABLET;ORAL	019668-003	Nov 2, 1990	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for CARDURA

See the table below for patents covering CARDURA around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
Czechoslovakia	207671	METHOD OF MAKING THE PIPERAZINYLCHINAZOLINE DERIVATIVES	⤷ Sign Up
Czechoslovakia	9103544		⤷ Sign Up
Croatia	P931467	PROCESS FOR THE PREPARATION OF ANTIHYPERTENSITIVE CHINAZOLINE	⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration

AI Research Assistant

Questions you can ask:

Summary for CARDURA

Recent Clinical Trials for CARDURA

Pharmacology for CARDURA

Make Better Decisions: Try a trial or see plans & pricing